Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN S HROM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1134238496
CMS profile
232451
Location
HATTIESBURG, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,153.74

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,153.74 109

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN S HROM

NPI 1134238496 · CMS profile ID 232451

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HATTIESBURG, MS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134238496?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN S HROM, NPI 1134238496, CMS profile ID 232451. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134238496?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN S HROM, NPI 1134238496, CMS profile ID 232451. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134238496?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN S HROM, NPI 1134238496, CMS profile ID 232451, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1134238496?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $2,153.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $19.3108/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944195793 CMS
Octapharma USA, Inc. $17.1407/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937553241 CMS
Astellas Pharma US Inc $13.0507/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940236867 CMS
PFIZER INC. $17.0807/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949201819 CMS
Rigel Pharmaceuticals, Inc. $14.5307/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962276585 CMS
Genentech USA, Inc. $27.5707/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950712455 CMS
SECURA BIO, INC. $13.3107/13/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 964233475 CMS
E.R. Squibb & Sons, L.L.C. $15.8507/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932588377 CMS
Merck Sharp & Dohme LLC $24.1207/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944285853 CMS
Genentech USA, Inc. $19.2206/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950714487 CMS
Sobi, Inc $12.4406/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940371767 CMS
Alexion Pharmaceuticals, Inc. $114.8406/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914872411 CMS
GlaxoSmithKline, LLC. $17.5006/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945213873 CMS
Janssen Biotech, Inc. $14.8006/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886105859 CMS
Karyopharm Therapeutics Inc. $20.8306/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946520173 CMS
EISAI INC. $17.4506/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908048945 CMS
Astellas Pharma US Inc $16.1806/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940203745 CMS
E.R. Squibb & Sons, L.L.C. $12.0906/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932588371 CMS
Gilead Sciences, Inc. $43.0006/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929589949 CMS
GlaxoSmithKline, LLC. $23.0905/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945213875 CMS
Gilead Sciences, Inc. $15.4505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929589947 CMS
Novartis Pharmaceuticals Corporation $16.7205/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893760927 CMS
Amgen Inc. $16.0705/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939861989 CMS
Kite Pharma, Inc. $15.7605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920058061 CMS
ADC Therapeutics America, Inc. $13.2305/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060941537 CMS
Incyte Corporation $24.6605/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032197 CMS
Amgen Inc. $20.0005/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939861981 CMS
Janssen Pharmaceuticals, Inc $19.4004/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886509571 CMS
Seagen Inc. $23.4704/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904120235 CMS
Merck Sharp & Dohme LLC $19.6704/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944295703 CMS
Pharmacyclics LLC, an AbbVie Company $19.5704/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890341305 CMS
Karyopharm Therapeutics Inc. $30.2004/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946520167 CMS
Incyte Corporation $11.7404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943032189 CMS
Blueprint Medicines Corporation $17.3904/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958934247 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.9304/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955659901 CMS
JAZZ PHARMACEUTICALS INC. $21.0404/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951357623 CMS
EMD Serono, Inc. $12.9404/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941503687 CMS
Amgen Inc. $17.2704/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939247993 CMS
Celgene Corporation $14.8403/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932588367 CMS
Nestle HealthCare Nutrition Inc. $13.7303/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902779953 CMS
E.R. Squibb & Sons, L.L.C. $14.1203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932588359 CMS
Janssen Biotech, Inc. $36.9203/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886105847 CMS
Ipsen Biopharmaceuticals, Inc $24.5603/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893389899 CMS
Pharmacosmos Therapeutics Inc. $14.2003/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959141811 CMS
BeiGene USA, Inc. $17.2903/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940796205 CMS
Sobi, Inc $13.7403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940371775 CMS
GlaxoSmithKline, LLC. $19.1702/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945213871 CMS
Daiichi Sankyo Inc. $19.0002/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930804473 CMS
Janssen Biotech, Inc. $13.0902/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886105865 CMS
JAZZ PHARMACEUTICALS INC. $23.4402/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951349879 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,500.43 102
PY2020 $552.06 27
PY2021 $815.42 50
PY2022 $2,153.74 109
PY2023 $2,446.76 118
PY2024 $1,710.38 77
PY2025 $1,379.37 64

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $73.00 2
PY2025 Principal investigator $1,437,415.12 176
PY2024 Recipient $768.71 2
PY2024 Principal investigator $1,138,869.99 139
PY2023 Recipient $111.00 4
PY2023 Principal investigator $965,036.70 82
PY2022 Principal investigator $865,848.90 73
PY2021 Principal investigator $1,897,381.57 88
PY2020 Principal investigator $1,471,650.77 234
PY2019 Principal investigator $2,249,708.72 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

178 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $216.00 12/31/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202532386
Principal investigator 1 Merck Sharp & Dohme LLC $187,257.16 12/31/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology,Oncology
A Randomized, Open label, Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer with PD-L1 TPS Greater Than or Equal To 50 No dispute reported 06/30/2026 1232923232
Principal investigator 1 Merck Sharp & Dohme LLC $9,161.59 12/31/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology,Oncology
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations No dispute reported 06/30/2026 1232923486
Principal investigator 1 Merck Sharp & Dohme LLC $19,620.02 12/31/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology,Oncology
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm No dispute reported 06/30/2026 1232928672
Principal investigator 1 Merck Sharp & Dohme LLC $8,433.80 12/31/2025 Non-covered Recipient Entity
Hattiesburg Clinic
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931250
Principal investigator 1 BeOne Medicines USA, Inc. $624.00 12/30/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190337428
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,500.00 12/29/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC HEMATOLOGY AND ONCOLOGY
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185548343
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 12/19/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184278054
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,664.00 12/18/2025 Non-covered Recipient Entity
Hattiesburg Clinic Family Practice
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1235997015
Principal investigator 1 ABBVIE INC. $5,116.80 12/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202527194
Principal investigator 1 ABBVIE INC. $2,401.75 12/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma No dispute reported 06/30/2026 1202527196
Principal investigator 1 Incyte Corporation $1,402.96 12/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC HEM
INCB50465-801, Ph2, Roll-Over Study No dispute reported 06/30/2026 1240538030
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,391.00 12/03/2025 Non-covered Recipient Entity
Hattiesburg Clinic - Hattiesburg
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235997017
Principal investigator 1 Janssen Research & Development, LLC $12,351.00 12/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175398602
Principal investigator 1 Janssen Research & Development, LLC $10,099.00 11/28/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175398678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,137.85 11/27/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184265595
Principal investigator 1 ABBVIE INC. $4,102.80 11/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202524782
Principal investigator 1 ABBVIE INC. $3,000.01 11/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202525050
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 11/17/2025 Non-covered Recipient Entity
Forrest General Hospital Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190337172
Principal investigator 1 ABBVIE INC. $2,393.30 11/05/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202521725
Principal investigator 1 ABBVIE INC. $14,379.30 11/05/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202521727
Principal investigator 1 PFIZER INC. $3,900.00 11/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228730500
Principal investigator 1 Janssen Research & Development, LLC $3,368.00 11/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 10/29/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184254343
Principal investigator 1 BeOne Medicines USA, Inc. $624.00 10/28/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190337425
Principal investigator 1 Janssen Research & Development, LLC $285.00 10/24/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398616
Principal investigator 1 Incyte Corporation $1,188.72 10/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC HEM
INCB50465-801, Ph2, Roll-Over Study No dispute reported 06/30/2026 1240538023
Principal investigator 1 Incyte Corporation $3,000.00 10/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC HEM
INCB50465-801, Ph2, Roll-Over Study No dispute reported 06/30/2026 1240538027
Principal investigator 1 Merck Sharp & Dohme LLC $3,060.00 10/22/2025 Non-covered Recipient Entity
Hattiesburg Clinic
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies No dispute reported 06/30/2026 1232931248
Principal investigator 1 Janssen Research & Development, LLC $19,224.00 10/13/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398656
Principal investigator 1 ABBVIE INC. $4,967.30 10/09/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202514193
Principal investigator 1 ABBVIE INC. $9,965.80 10/09/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202514195
Principal investigator 1 BeOne Medicines Ltd. $1,512.00 10/08/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies No dispute reported 06/30/2026 1190329271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 10/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184245381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 10/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184245383
Principal investigator 1 BeOne Medicines USA, Inc. $1,248.00 09/23/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190337419
Principal investigator 1 Janssen Research & Development, LLC $13,429.00 09/22/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175398725
Principal investigator 1 Janssen Research & Development, LLC $7,445.00 09/19/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175398661
Principal investigator 1 ABBVIE INC. $9,916.40 09/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202509332
Principal investigator 1 ABBVIE INC. $2,393.30 09/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202509802
Principal investigator 1 BeOne Medicines USA, Inc. $1,964.00 09/02/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190337414
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233284
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,106.50 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,668.55 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.30 09/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184233296
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 08/25/2025 Non-covered Recipient Entity
Forrest General Hospital Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190344188
Principal investigator 1 Janssen Research & Development, LLC $1,914.00 08/25/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398740
Principal investigator 1 Janssen Research & Development, LLC $10,389.00 08/11/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175398565
Principal investigator 1 ABBVIE INC. $10,078.90 08/06/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202502492
Principal investigator 1 ABBVIE INC. $3,152.50 08/06/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202502494
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 08/05/2025 Non-covered Recipient Entity
Forrest General Hospital Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330205
Principal investigator 1 SANOFI US SERVICES INC. $1,548.00 08/04/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089832
Principal investigator 1 BeOne Medicines Ltd. $3,000.00 08/01/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327123
Principal investigator 1 BeOne Medicines Ltd. $1,000.00 08/01/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327297
Principal investigator 1 BeOne Medicines Ltd. $609.00 08/01/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190327305
Principal investigator 1 Janssen Research & Development, LLC $13,895.00 07/24/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398733
Principal investigator 1 ABBVIE INC. $9,639.65 07/10/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202497952
Principal investigator 1 ABBVIE INC. $9,916.40 07/08/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202497298
Principal investigator 1 SANOFI US SERVICES INC. $2,350.00 07/07/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089826
Principal investigator 1 Janssen Research & Development, LLC $9,457.00 07/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175398642
Principal investigator 1 Celgene Corporation $22,455.00 06/27/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305262
Principal investigator 1 Janssen Research & Development, LLC $16,674.00 06/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398650
Principal investigator 1 BeOne Medicines Ltd. $1,512.00 06/20/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190326216
Principal investigator 1 BeOne Medicines USA, Inc. $777.00 06/17/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190326080
Principal investigator 1 ABBVIE INC. $8,606.40 06/12/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202491365
Principal investigator 1 BeOne Medicines Ltd. $52,400.00 06/09/2025 Non-covered Recipient Entity
Forrest General Hospital Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190330273
Principal investigator 1 ABBVIE INC. $10,078.90 06/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202489787
Recipient ABBVIE INC. $48.00 05/30/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202398921
Recipient ABBVIE INC. $25.00 05/30/2025 Covered Recipient Physician A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202398925
Principal investigator 1 ABBVIE INC. $8,305.80 05/28/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202486457
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,057.86 05/27/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology Oncology
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235997011
Principal investigator 1 Janssen Research & Development, LLC $8,337.00 05/26/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $323.70 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $596.70 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $419.90 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $533.00 05/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184198443
Principal investigator 1 BeOne Medicines USA, Inc. $15,688.00 05/12/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190331411
Principal investigator 1 ABBVIE INC. $4,706.00 05/07/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202482813
Principal investigator 1 SANOFI US SERVICES INC. $3,700.00 05/05/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,423.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,423.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $596.70 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,574.00 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,005.30 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,876.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,616.90 05/01/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184191721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,425.70 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190869
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,566.30 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.30 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,649.90 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,104.60 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,649.90 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,329.75 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,424.75 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,329.75 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $108.30 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,425.70 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,649.90 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,201.50 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,175.60 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.35 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,566.30 04/30/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184190917
Principal investigator 1 Celgene Corporation $46,588.50 04/25/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology And Oncology
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1222304491
Principal investigator 1 ABBVIE INC. $7,229.70 04/24/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202479111
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $58,319.00 04/24/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology Oncology
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers No dispute reported 06/30/2026 1235997009
Principal investigator 1 Incyte Corporation $2,971.80 04/24/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC HEM
INCB50465-801, Ph2, Roll-Over Study No dispute reported 06/30/2026 1240538018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,768.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184186231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,900.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184186233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,302.40 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184186235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,702.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS No dispute reported 06/30/2026 1184186237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,900.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184186239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,702.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184186241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,302.40 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184186243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,768.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC
A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184186245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,986.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184189017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,525.00 04/23/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184189019
Principal investigator 1 Janssen Research & Development, LLC $5,558.00 04/21/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398591
Principal investigator 1 ABBVIE INC. $4,163.90 04/17/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202477250
Principal investigator 1 BeOne Medicines USA, Inc. $1,248.00 04/17/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia No dispute reported 06/30/2026 1190326082
Principal investigator 1 Celgene Corporation $8,976.50 04/17/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology And Oncology
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222304561
Principal investigator 1 BeOne Medicines USA, Inc. $39,628.00 04/16/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190338170
Principal investigator 1 BeiGene, Ltd. $33,536.00 04/16/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190322296
Principal investigator 1 ABBVIE INC. $12,000.10 04/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202471558
Principal investigator 1 ABBVIE INC. $10,078.90 04/03/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202471561
Principal investigator 1 SANOFI US SERVICES INC. $3,519.00 04/02/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089808
Principal investigator 1 Janssen Research & Development, LLC $2,779.00 03/24/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398706
Principal investigator 1 ABBVIE INC. $10,445.90 03/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202465049
Principal investigator 1 ABBVIE INC. $10,291.15 03/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202465078
Principal investigator 1 Celgene Corporation $1,910.00 03/19/2025 Non-covered Recipient Entity
Advarra
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1222307115
Principal investigator 1 BeiGene, Ltd. $52,400.00 03/17/2025 Non-covered Recipient Entity
Forrest General Hospital Cancer Center
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190323682
Principal investigator 1 BeiGene, Ltd. $1,512.00 03/14/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320076
Principal investigator 1 ABBVIE INC. $12,862.85 03/12/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M18-868 - A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202462673
Principal investigator 1 SANOFI US SERVICES INC. $2,968.00 03/10/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089814
Principal investigator 1 ABBVIE INC. $26,800.80 03/07/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202460136
Principal investigator 1 ABBVIE INC. $17,020.90 03/07/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M24-977 - A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (AndroMETa-GEA) No dispute reported 06/30/2026 1202460278
Principal investigator 1 BioNTech SE $8,000.00 03/04/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
BNT327-01 No dispute reported 06/30/2026 1249011548
Principal investigator 1 Celgene Corporation $12,378.00 02/21/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial No dispute reported 06/30/2026 1222305306
Principal investigator 1 Janssen Research & Development, LLC $2,779.00 02/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398586
Principal investigator 1 SANOFI US SERVICES INC. $2,867.00 02/18/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089794
Principal investigator 1 BeiGene, Ltd. $1,512.00 02/14/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320000
Principal investigator 1 ABBVIE INC. $2,835.30 02/06/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202447175
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,201.16 01/27/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology Oncology
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) No dispute reported 06/30/2026 1235997005
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,971.74 01/27/2025 Non-covered Recipient Entity
Hattiesburg Clinic Hematology Oncology
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 No dispute reported 06/30/2026 1235997007
Principal investigator 1 SANOFI US SERVICES INC. $3,476.00 01/27/2025 Non-covered Recipient Entity
Hattiesburg Clinic, Pa
A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226089800
Principal investigator 1 Janssen Research & Development, LLC $2,779.00 01/20/2025 Non-covered Recipient Entity
HATTIESBURG CLINIC PA
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer No dispute reported 06/30/2026 1175398709
Principal investigator 1 BeiGene, Ltd. $325.00 01/15/2025 Non-covered Recipient Entity
Hattiesburg Hematology and Oncology Clinic
An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies No dispute reported 06/30/2026 1190320004